
Midatech Pharma plc MTP
Geschäftsbericht 2024
hinzugefügt 21.02.2026
Midatech Pharma plc Operativer Cashflow 2011-2026 | MTP
Operativer Cashflow Jährlich Midatech Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -6.01 M | -9.3 M | -6.49 M | -13.4 M | -13 M | -13.1 M | -12.4 M | - | - | - | - |
Alle Zahlen in GBP-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -6.01 M | -13.4 M | -10.5 M |
Operativer Cashflow anderer Aktien in der Pharmaeinzelhändler
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
-131 M | $ 3.54 | -2.48 % | $ 1.06 B | ||
|
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
50.4 M | $ 15.85 | -4.2 % | $ 3.78 B | ||
|
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
-1.19 M | $ 0.82 | -0.79 % | $ 4.47 M | ||
|
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.39 | 2.67 % | $ 2.57 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
64 M | $ 75.33 | -1.57 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.53 | -6.44 % | $ 390 M | ||
|
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | ||
|
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
142 M | $ 34.4 | -3.61 % | $ 3.57 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-36.1 M | $ 7.77 | -7.72 % | $ 33.6 M | ||
|
Axsome Therapeutics
AXSM
|
-93.4 M | $ 162.29 | -1.09 % | $ 8.07 B | ||
|
CorMedix
CRMD
|
-38.4 M | $ 6.52 | -8.43 % | $ 332 M | ||
|
Champions Oncology
CSBR
|
7.39 M | $ 5.85 | -2.58 % | $ 79.9 M | ||
|
BridgeBio Pharma
BBIO
|
-446 M | $ 64.94 | -2.41 % | $ 12.4 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.09 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B | ||
|
Denali Therapeutics
DNLI
|
-348 M | $ 19.72 | -3.19 % | $ 3.24 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | ||
|
Edesa Biotech
EDSA
|
-4.89 M | $ 3.91 | -8.43 % | $ 12.5 M | ||
|
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
-17.8 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.86 | 1.78 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
828 M | $ 60.59 | 0.26 % | $ 11.6 B | ||
|
Equillium
EQ
|
-21.8 M | $ 1.7 | -3.14 % | $ 59 M | ||
|
Burford Capital Limited
BUR
|
181 M | $ 8.22 | -1.85 % | $ 1.35 B |